Current prognostic factors for prostate carcinoma

Cancer

Volumn 78, Issue 2, 1996, Pages 341-344

  Montie, James E ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Department of Surgery/Urology ^*  (United States)

Author keywords

outcome; prognostic factors; prostate carcinoma; prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; DNA DETERMINATION; PATIENT CARE; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; TRANSRECTAL ULTRASONOGRAPHY;

AGE FACTORS; CARCINOMA; COMORBIDITY; HUMANS; MALE; NEOPLASM STAGING; PLOIDIES; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0030036589     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960715)78:2<341::AID-CNCR24>3.0.CO;2-V     Document Type: Conference Paper

References (24)

1. Fielding LP, Fenoglio-Preiser CM, Freedman LS. The future of prognostic factors in outcome prediction for patients with cancer. Cancer 1992;70:2367.
2. Burke HB, Henson DE. Criteria for prognostic factors and for an enhanced prognostic system. Cancer 1993;72:3131.
3. Fielding LP, Henson DE. Multiple prognostic factors and outcome analysis in patients with cancer. Cancer 1993; 71:2426.
4. Montie JE, Pienta KJ, Pontes JE. Staging systems and prognostic factors for prostate cancer. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, editors. Comprehensive textbook of genitourinary oncology. Baltimore: Williams and Wilkins Co., 1996. In press.
5. Grignon DJ, Hammond EH. College of American Pathologists Conference XXVI on Clinical Relevance of Prognostic Markers in Solid Tumors. Arch Pathol Lab Med 1995;XX:119.
6. Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994;69:977.
7. Altman DG, Larsen B, Saubrei W, Schumacker M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994;86:829.
8. Zagars GK, von Eschenbach AC, Avala AG. Prognostic factors in prostate cancer. Cancer 1993;72:1709.
9. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995;274:626.
10. Montie JE. 1992 staging system for prostate cancer. Semin Urol 1993;XI:10.
11. Montie JE. Staging of prostate cancer: current TNM classification and future prospects for prognostic factors. Cancer 1995;75(Suppl):1814.
12. Corn BW, Hanks GE, Lee WR, Schultheiss T. Do the current subclassifications of stage T3 adenocarcinoma of the prostate have clinical relevance? Urology 1995;45:484.
13. Ferguson JK, Bostwick DG, Suman V, Zincke H, Oesterling JE. Prostate-specific antigen detected prostate cancer-pathologic characteristics of ultrasound visible versus ultrasound invisible tumors. Eur Urol 1995;27:8.
14. Huland H, Hammerer P, Henke R-P, Huland E. Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal examination, prostate specific antigen and the results of 6 systematic biopsies. J Urol 1996;155:1344.
15. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993:71(11):3582.
16. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994;152:1358.
17. Adolfsson J. Prognostic value of deoxyribonucleic acid content in prostate cancer: a review of current results. Int J Cancer 1994;58:211.
18. Carmichael MJ, Veltri RW, Partin AW, Miller MC, Walsh PC, Epstein JI. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 1995;153:1015.
19. Stamey TA. DNA ploidy status. Urology 1995;45:563.
20. Lieber MM. Practical clinical utility of DNA ploidy for managing patients with prostate carcinoma. Urology 1995; 45:558.
21. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110.
22. Pisansky TM, Zincke H, Suman VJ, Bostwick DG, Earle JD, Oesterling JE. Correlation of pretherapy prostate cancer characteristics with histologie findings from pelvic lymphadenectomy specimens. Int J Radiat Oncol Biol Phys 1996; 34:33.
23. Partin AW, Piantadosi S, Sanda MG, Epstein JI, Marshall FF, Monier JL, et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. J Urol 1995;45:831.
24. Snow PB, Smith DS, Catalona WJ. Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. J Urol 1994;152:1923.